TY - JOUR
T1 - Uncovering patterns of inhaler technique and reliever use
T2 - the value of objective, personalized data from a digital inhaler
AU - Levy, Mark L.
AU - Kocks, Janwillem W.H.
AU - Bosnic-Anticevich, Sinthia
AU - Safioti, Guilherme
AU - Reich, Michael
AU - Depietro, Michael
AU - Castro, Mario
AU - Farooqui, Nabeel
AU - Lugogo, Njira L.
AU - Brown, Randall
AU - Hill, Tanisha
AU - Li, Thomas
AU - Chrystyn, Henry
N1 - Publisher Copyright:
© The Author(s) 2024.
PY - 2024/12
Y1 - 2024/12
N2 - Electronic inhalers provide information about patterns of routine inhaler use. During a 12-week study, 360 asthma patients using albuterol Digihaler generated 53,083 inhaler events that were retrospectively analyzed. A total of 41,528 (78%) of the recorded inhalation events were suitable for flow analysis (having a PIF ≥ 18 L/min and <120 L/min). Median PIF, inhalation volume, inhalation duration, and time to PIF for these events steadily decreased between the first and last 10 days of the study, by 5.1%, 12.6%, 15.9%, and 6.4%, respectively. Continuous short-acting beta2-agonist (SABA) overuse, defined as ≥2 SABA inhalations/week throughout the study period, was seen in 29% (n = 104) of patients. Of 260 patients with ≥1 instance of acute short-term SABA overuse, 55 (21%) had a confirmed exacerbation. Electronic recording of real-life inhaler use can capture valuable, objective information that could inform disease management and clinical decision-making.
AB - Electronic inhalers provide information about patterns of routine inhaler use. During a 12-week study, 360 asthma patients using albuterol Digihaler generated 53,083 inhaler events that were retrospectively analyzed. A total of 41,528 (78%) of the recorded inhalation events were suitable for flow analysis (having a PIF ≥ 18 L/min and <120 L/min). Median PIF, inhalation volume, inhalation duration, and time to PIF for these events steadily decreased between the first and last 10 days of the study, by 5.1%, 12.6%, 15.9%, and 6.4%, respectively. Continuous short-acting beta2-agonist (SABA) overuse, defined as ≥2 SABA inhalations/week throughout the study period, was seen in 29% (n = 104) of patients. Of 260 patients with ≥1 instance of acute short-term SABA overuse, 55 (21%) had a confirmed exacerbation. Electronic recording of real-life inhaler use can capture valuable, objective information that could inform disease management and clinical decision-making.
UR - http://www.scopus.com/inward/record.url?scp=85201603373&partnerID=8YFLogxK
U2 - 10.1038/s41533-024-00382-x
DO - 10.1038/s41533-024-00382-x
M3 - Article
C2 - 39164292
AN - SCOPUS:85201603373
SN - 2055-1010
VL - 34
JO - npj Primary Care Respiratory Medicine
JF - npj Primary Care Respiratory Medicine
M1 - 23
ER -